India, April 15 -- Drug major Johnson & Johnson (JNJ), while reporting significantly higher first-quarter earnings with increased sales, on Tuesday maintained its outlook for fiscal 2025 adjusted earnings, but trimmed adjusted operational earnings view.
Further, the company raised sales outlook on a reported and operational basis, but maintained adjusted operational sales growth view.
Separately, Johnson & Johnson announced that its Board of Directors has declared a 4.8 percent increase in the quarterly dividend to $1.30 per share from $1.24 per share last year.
In pre-market activity on the NYSE, JNJ shares were gaining around 1.3 percent to trade at $156.30.
At the new rate, the indicated dividend on an annual basis is $5.20 per share...